节点文献
得力生注射液联合化疗治疗晚期消化道肿瘤的临床观察
The clinical study on Treatment of DLS combined with chemotherapy for advanced gastrointestinal cancer
【摘要】 目的:探讨得力生注射液(DeLiShengInjection,简称DLS)联合化疗治疗晚期消化道肿瘤的临床疗效。方法:60例晚期消化道肿瘤患者随机分组为化疗组(对照组)和化疗联合得力生组(试验组),其中试验组30例,奥沙利铂135mg/m2+5%葡萄糖溶液(GS)250ml静滴,d1;亚叶酸钙(CF)100mg+5%GS250ml静滴,d1~d5;氟尿嘧啶(5FU)0.5g+5%GS500ml静滴,d1~d5。化疗当天给予得力生注射液20~40ml加入5%GS500ml静滴d1~d21。常规予5HT3受体抑制剂止吐,21~28天为1周期。对照组30例,化疗方案同治疗组。结果:对照组总有效率和生活质量改善率分别为39.4%和42.4%,试验组分别为63.9%和66.7%,两组比较有显著性差异(P<0.05);对照组白细胞减少为75.8%,高于试验组的52.8%;对照组治疗后CD3+、CD4+、CD4+/CD8+降低,CD8+增高,治疗前后对比有非常显著性差异(P<0.01),而试验组治疗前后无显著性差异。结论:得力生联合化疗可显著提高化疗疗效,增强机体免疫功能,改善患者的生存质量,且不增加骨髓抑制。
【Abstract】 Objective:To study the effects of De Li Sheng Injection with chemotherapy in the treatment of gastrointestinal cancer.Methods:60 cases of advanced gastrointestinal cancers were randomly divided into two groups,30 patients in control group (chemotherapy),30 patients in test group(De Li Sheng Injectable combined with chemotherapy ).Results:Total remission rate and improvement rate of quality of life of control guoup were 39.4% and 42.4% respectively,while they were 63.9% and 66.7% respectively in test group. Test group was obviously superior to control group in therapeutic effect (P<0.05).The leucocyte decrease rate of control group was 75.8% which was higher than 52.8% in test group(P<0.05). CD_ 3~+、CD_ 4~+、CD_ 4~+/CD_ 8~+decreased, CD_ 8~+ascended(P<0.01) in control group and it changed slightly in test group. Conclusion:DLS conbined with chemotherapy may significantly enhance the chemotherapy effects ,increase immunity function of patients, improve the quality of life, whereas do not increase myelosuppresion.
- 【文献出处】 临床肿瘤学杂志 ,Chinese Clinical Oncology , 编辑部邮箱 ,2006年07期
- 【分类号】R735
- 【被引频次】6
- 【下载频次】63